Neuroscience

#Neurodevelopmental disorders #Neuroscience #Phase III trial #Rare disease #UCB

UCB reports positive results for neurodevelopmental disorder

Global biopharmaceutical company UCB has reported positive data for its Phase III GEMZ study which is investigating adjunctive fenfluramine in children and adults with CDKL5 Deficiency Disorder (CDD).   The data were announced at the American Epilepsy Society (AES) meeting, Atlanta, USA.  The results… Read More

#Editor's Choice #News

MRI of dementia patient
#Alzheimer's #Biomarkers #Duke University #Neurodegenerative disorders #Neuroscience

Study supports hippocampal volume as marker in Alzheimer’s

A new study has revealed that hippocampal volume (HV) may be a reliable and measurable surrogate used to assess clinical benefits in early Alzheimer’s disease.  The study results, published in the scientific journal CNS Drugs, show that shrinkage of the hippocampus… Read More

#Editor's Choice #News

Stem cells
#Assays #Drug development #Drug discovery #iPSC-derived cells #Neuroscience

Technical Guide: Introducing the Brain-Chip R1

A new Technical Guide is now available from Emulate entitled ‘Characterization of the Brain-Chip R1: A First-in-Class, Isogenic Model of the Human Neurovascular Unit‘. Key highlights: Incorporates five iPSC-derived cell types, including proprietary BMECs that exhibit a physiologically relevant brain microvascular endothelial-like phenotype Maintains resting-state glia and a tight,… Read More

#News

#Assays #Drug development #Drug discovery #iPSC-derived cells #Neuroscience

Introducing the Brain-Chip R1: A new era for human-relevant BBB & NVU research

Key highlights: Incorporates five iPSC-derived cell types, including proprietary BMECs that exhibit a physiologically relevant brain microvascular endothelial-like phenotype Maintains resting-state glia and a tight, stable barrier throughout a four-day experimental window Features a streamlined, 12-day direct-to-chip workflow with no pre-plating or expansion steps, enabling robust and reproducible performance… Read More

#Resources #Technical Notes

#Neuroscience

Technical Guide – Introducing the Brain-Chip R1: A New Era for Human-Relevant BBB & NVU Research

Key highlights: Incorporates five iPSC-derived cell types, including proprietary BMECs that exhibit a physiologically relevant brain microvascular endothelial–like phenotype Maintains resting-state glia and a tight, stable barrier throughout a four-day experimental window Features a streamlined, 12-day direct-to-chip workflow with no pre-plating or expansion steps,… Read More

#Guides

Neurons in the brain
#Amyotrophic lateral sclerosis (ALS) #Appointment #Neuroscience #New appointment #NRG Therapeutics

NRG Therapeutics appoints Paul Thompson as CDO

NRG Therapeutics has expanded its team with the appointment of Paul Thompson PhD as Chief Development Officer (CDO).  In his role at NRG, Thompson will be project lead for NRG5051 which is on track to commence first-in-human studies in early 2026.   NRG5051 is an oral,… Read More

#News

Neuronal network
#Drug discovery #eBook #Neurodegenerative disorders #Neuroscience #Psychiatry

eBook: What’s new in neuroscience drug discovery?

The global neuroscience market has grown significantly in the last 10 years, driven predominantly by an ageing population and increasing cases of neurodegenerative diseases like Alzheimer’s disease (AD). The neuroscience market size was estimated at $44.65 billion in 2023 and is projected to reach $65.22 billion by 2030,… Read More

#News

DDW Neuroscience book cover
#Drug discovery #eBook #Neurodegenerative disorders #Neuroscience #Psychiatry

What’s new in neuroscience drug discovery?

This eBook, sponsored by Emulate, explores the latest developments in our understanding of neuroscience and the new therapies coming to market, spanning neurodegenerative diseases, genetic disorders, and psychiatry.

#DDW eBooks #Intelligence

#Neuroscience

Whitepaper – Navigating Neurological Biomarker Research: Progress, Learnings and Future Directions

Neurological biomarker research is advancing rapidly, but key challenges remain. This whitepaper captures: Expert perspectives from academia and biopharma Highlighting successes, setbacks, and strategies for translational advancements in Alzheimer’s, Parkinson’s, and MS. A must-read for researchers navigating the future of precision neurology.   Brought to… Read More

#Whitepapers

#Neuroscience #NRG Therapeutics

NRG Therapeutics announces senior appointments

Neuroscience company NRG Therapeutics has announced an expansion to its senior team as it advances its neurodegenerative disease treatment NRG5051.  Sarah Almond has been appointed as VP of Translational Biology, David Brocklebank as Director of Clinical Operations, and Kathryn Oliver as Director of Project Management. … Read More

#News

Brain physiology
#Neurodegenerative disorders #Neuroscience #Parkinson's #Phase I trial

Early-stage advances in Parkinson’s drug discovery

A number of key clinical and preclinical study results into potential Parkinson’s disease (PD) therapeutics were announced at the International Congress of Parkinson’s Disease and Movement Disorders.  Unexpected early results for allosteric enzyme modulator Gain Therapeutics shared encouraging early results from the Phase Ib clinical study of GT-02287 in people… Read More

#Exclusive Content

#Alzheimer's #Neuroscience

The promise of gene therapies in Alzheimer’s 

DDW Editor Reece Armstrong speaks to Brian Head, Professor of Anesthesiology at UC San Diego School of Medicine and Veterans Affairs Research Career Scientist, about challenges in Alzheimer's drug discovery and how gene therapy research could provide promise for this challenging treatment area.     RA: Why are early-stage, preventative treatments… Read More

#Exclusive Content

Human brain
#Biomarkers #Drug discovery #Neurology #Neuroscience #Whitepaper

Navigating neurological biomarker research: Download the Whitepaper

Neurological biomarker research is advancing rapidly, but key challenges remain. Download this new Whitepaper from Olink entitled ‘Navigating neurological biomarker research: Progress, learnings and future directions’. The Whitepaper captures: Expert perspectives from academia and biopharma Highlighting successes, setbacks, and strategies for translational advancements in Alzheimer’s, Parkinson’s, and MS. A… Read More

#News

#Biomarkers #Drug discovery #Neurology #Neuroscience #Whitepaper

Navigating neurological biomarker research: Progress, learnings and future directions

Neurological biomarker research is advancing rapidly, but key challenges remain. This Whitepaper captures: Expert perspectives from academia and biopharma Highlighting successes, setbacks, and strategies for translational advancements in Alzheimer’s, Parkinson’s, and MS. A must-read for researchers navigating the future of precision neurology. Read More

#Resources #Whitepapers

Neuroscience innovation
#Ageing #Mass spectrometry / NMR #Neuroscience #Protein chemistry / Proteomics #Proteomics

Deciphering proteome alterations in neurodegeneration with mass spectrometry 

Daniel Hornburg PhD, Vice-President Biomarkers & Precision Medicine, Bruker Daltonics, Stefan Foser, Vice President Global Pharma, Bruker Daltonics, and Torsten Müller, Business Development Manager, Proteomics, Bruker Daltonics, explore how MS-based proteomics can be used to dissect disease biology with spatial resolution.   Impact of neurodegeneration for ageing societies Neurological conditions have… Read More

#Exclusive Content

Neuron
#Gain Therapeutics #Neurodegenerative disorders #Neuroscience #Parkinson's #Phase I trial

Early data suggest GT-02287 slows Parkinson’s disease

Gain Therapeutics has shared early safety and tolerability findings, the primary endpoint, and observations from key exploratory endpoints from the Phase Ib clinical study of GT-02287 in people with Parkinson’s disease (PD) with or without a GBA1 mutation.  The findings were presented in a poster at the… Read More

#News #Trending News